Video

How Long Should Tocilizumab Be Continued for Patients with Giant Cell Arteritis?

Author(s):

John Stone, MD, Massachusetts General Hospital, discussed study results and fear surrounding giant cell arteritis.

"Giant cell arteritis is a disease that has huge unmet need ever since cortisone was invented 67 years ago," said John Stone, MD, Massachusetts General Hospital. Stone explained that the only existing treatment, glucocorticoids (prednisone), while effective, is associated with a host of side effects, making it difficult to maintain patients on prednisone for a long period of time. Stone and his team embarked on the GiACTA study, whose goal was to demonstrate that tocilizumab had a powerful "steroid-sparing" effect. To test their hypothesis, the team embarked on a trial with four arms and 251 patients.

According to Stone, one of the most striking findings was that in the steroid-only arm (in the patients who received one full year of steroids) only 18% of patients were in sustained remission at one year. Also, the tocilizumab group faired much better with regard to achievement of sustaining remission. Stone believed that the take-home point should be that when physicians diagnose patients with giant cell arteristis, they need to think not only of steroids immediately; instead they need to think about promptly beginning tocilizumab. It's important to note that all the while, the patient is absorbing the toxicity of the glucocorticoid, so it's important to think about using both of the medicines together and eventually tapering the steroids off as quickly as possible.

Stone shared that one of the exciting questions in the months and years to come is how little glucocorticoid they can use in treating these patients, and about how long tocilizumab should be continued - something they plan to study in the second leg of the trial.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.